Related Experiment Video

Updated: May 9, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind,

Jemma Anderson, Alexia S Peña, Thomas Sullivan

    BMC Pediatrics
    |July 20, 2013
    PubMed

    Insights

    This study investigates metformin

    Area of Science:

    • Pediatric Endocrinology
    • Cardiovascular Research
    • Metabolic Disorders

    Background:

    • Cardiovascular disease (CVD) is the primary cause of death in children with Type 1 diabetes (T1D).
    • Vascular dysfunction is an early indicator of CVD in T1D, necessitating early interventions.
    • Metformin, an insulin-sensitizing drug, shows promise for improving vascular health, with a proven safety record in pediatric Type 2 diabetes.

    Purpose of the Study:

    • To assess the efficacy of metformin in improving vascular health among children diagnosed with Type 1 diabetes.
    • To evaluate metformin's impact on key vascular and biochemical markers in this pediatric population.

    Main Methods:

    • A 12-month, double-blind, randomized, placebo-controlled trial involving 76 children (ages 8-18) with T1D.
    • Participants were divided into two groups: 38 receiving metformin and 38 receiving a placebo.
    • Vascular health was assessed using flow-mediated dilation, glyceryl trinitrate-mediated dilation, and intima-media thickness measurements at baseline and at 3, 6, and 12 months.

    Main Results:

    • Data collection and analysis are ongoing.
    • Interim results will be presented upon completion of the 12-month study period.

    Conclusions:

    • This trial is the first to examine metformin's effects on vascular health in children with T1D.
    • Findings are expected to provide crucial insights into a potential therapeutic strategy for reducing cardiovascular risk in this high-risk group.
    Abstract

    Related Concept Videos

    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    Diabetes Mellitus: Overview and Type I Subtype01:22

    Diabetes Mellitus: Overview and Type I Subtype

    Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
    Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
    Type I Diabetes II: Pathophysiology01:26

    Type I Diabetes II: Pathophysiology

    Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
    Type II Diabetes II: Pathophysiology01:24

    Type II Diabetes II: Pathophysiology

    PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.